CABA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cabaletta Bio Inc (CABA) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some bullish momentum, the lack of significant positive catalysts, weak financial performance, and absence of recent influential trading activity do not support an immediate investment decision. Holding off for now is recommended.
The MACD histogram is positive at 0.0682 and expanding, indicating bullish momentum. RSI is at 77.248, in the neutral zone. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 3.145, R1: 3.611, S1: 2.679, R2: 3.899, S2: 2.391. However, the stock has a 50% chance of declining -1.1% in the next day and -1.01% in the next week, with a slight potential for a 4.82% gain in the next month.
The MACD and moving averages indicate bullish momentum. Analyst rating from Morgan Stanley remains Overweight, with a revised price target of $14, suggesting long-term potential.
EPS dropped by -29.03% YoY. Options data shows minimal put activity, indicating low bearish sentiment but also limited enthusiasm.
In Q3 2025, revenue remained at $0 with no growth. Net income improved by 46.48% YoY but remains negative at -$44.87M. EPS declined by -29.03% YoY to -0.44. Gross margin is 0, showing no profitability.
Morgan Stanley lowered the price target from $22 to $14 but maintained an Overweight rating, citing potential in the U.S. small-to-mid cap biotech sector as it transitions from capital consumers to producers.
